Basilea Pharmaceutica AG (BSLN) — Cash Flow Reinvestment Rate

Latest as of December 2025: 0.06x

Basilea Pharmaceutica AG (BSLN) has a Cash Flow Reinvestment Rate of 0.06x as of December 2025, reinvesting CHF2.30 Million (capex CHF2.30 Million ) from operating cash flow of CHF39.03 Million. Check Basilea Pharmaceutica AG earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.06x
(Capex + Investments) / Operating CF

Total Reinvested

CHF2.30 Million
Capex + Investments

Operating Cash Flow

CHF39.03 Million
CHF

Capital Expenditures

CHF2.30 Million
CHF

Basilea Pharmaceutica AG Cash Flow Reinvestment Rate (2005–2025)

Historical reinvestment intensity for Basilea Pharmaceutica AG across 8 annual periods. Explore BSLN long-term investments to assets to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Basilea Pharmaceutica AG (2005–2025)

Year-by-year capital reinvestment analysis for Basilea Pharmaceutica AG. For live market cap and broader valuation context, see Basilea Pharmaceutica AG (BSLN) market capitalisation.

Year Reinvestment Rate Total Reinvested (CHF) Operating CF Capex YoY Change
2025 0.04x CHF2.62 Million CHF62.09 Million CHF2.62 Million ▲ +15.3%
2024 0.04x CHF2.72 Million CHF74.36 Million CHF1.71 Million ▼ -74.8%
2023 0.15x CHF2.07 Million CHF14.24 Million CHF1.03 Million ▼ -98.9%
2022 13.46x CHF94.95 Million CHF7.06 Million CHF3.30 Million ▲ +321.5%
2017 3.19x CHF60.71 Million CHF19.01 Million CHF711.00K ▲ +35705.9%
2012 0.01x CHF1.32 Million CHF148.17 Million CHF1.32 Million ▼ -23.3%
2010 0.01x CHF1.24 Million CHF106.64 Million CHF1.24 Million ▼ -66.7%
2005 0.03x CHF1.20 Million CHF34.38 Million CHF1.20 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow